FDC2024-07-012024-09-30 FDC2024-07-012024-09-30 FDC2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member FDC2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member FDC2024-09-30 FDC2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member FDC2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member FDC2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member FDC2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member FDC2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member FDC2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 531599 FDC NOTLISTED FDC Limited Equity 2024-04-01 2025-03-31 2024-11-06 2024-10-28 INR Lakhs Half yearly 12:30:00 15:50:00 2024-11-06 2024-11-06 true Cash Flow Indirect Not applicable Single segment npharmaceutical 2024-07-01 2024-09-30 Unaudited Consolidated 5138487000.00 347002000.00 5485489000.00 1399773000.00 326422000.00 104131000.00 1249504000.00 10738000.00 137909000.00 1357047000.00 4585524000.00 899965000.00 0.00 899965000.00 200071000.00 -20521000.00 179550000.00 0.00 720415000.00 0.00 0.00 0.00 0.00 720415000.00 13566000.00 733981000.00 733981000.00 0.00 733981000.00 0.00 162810000.00 1 4.43 0.00 0.00 0.00 4.43 0.00 1.The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the quarter and six months ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on November 6, 2024. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. 2. The Board of Directors of the Parent Company at their meeting held on November 6, 2024, has considered and approved the Interim Dividend of Rs. 5/- per equity share of face value of Rs. 1/- per equity share for the Financial Year 2024-25. 3.During the previous year, the Parent Company had completed the buyback of 31,00,000 equity shares having face value of Rs. 1/- each at a price of Rs. 500/- per share on September 13, 2023. The number of equity shares post buyback stands reduced to 16,28,10,084 shares having face value of Rs. 1/- each. Accordingly, the paid-up share capital also stands reduced to Rs. 16,28,10,084. 4. The Group has only one segment of activity namely Pharmaceuticals. 5. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 11521180000.00 631364000.00 12152544000.00 2756978000.00 688502000.00 694677000.00 2421631000.00 23696000.00 248150000.00 2791600000.00 9625234000.00 2527310000.00 0.00 2527310000.00 567185000.00 49360000.00 616545000.00 0.00 1910765000.00 0.00 0.00 0.00 0.00 1910765000.00 19289000.00 1930054000.00 1930054000.00 0.00 1930054000.00 0.00 162810000.00 1 11.74 0.00 0.00 0.00 11.74 0.00 Other Expenses 1357047000.00 Other Expenses 2791600000.00 7749262000.00 1432282000.00 255561000.00 0.00 35361000.00 6977000.00 0.00 0.00 5205184000.00 9542000.00 32812000.00 5247538000.00 683651000.00 15410632000.00 3228497000.00 5452448000.00 1734537000.00 444181000.00 11257000.00 13489000.00 123801000.00 7779713000.00 427668000.00 11435878000.00 34284000.00 0.00 26880794000.00 162810000.00 22754461000.00 22917271000.00 22917271000.00 0.00 0.00 112287000.00 112287000.00 317199000.00 229948000.00 0.00 0.00 659434000.00 0.00 1715083000.00 1125369000.00 2840452000.00 106019000.00 221350000.00 136268000.00 0.00 3304089000.00 0.00 0.00 3963523000.00 26880794000.00 23696000.00 660389000.00 -559256000.00 0.00 291585000.00 0.00 11570000.00 0.00 0.00 75005000.00 0.00 0.00 0.00 248150000.00 0.00 41344000.00 0.00 0.00 0.00 -2852000.00 0.00 204925000.00 0.00 -316836000.00 0.00 0.00 0.00 -60164000.00 0.00 207706000.00 2735016000.00 0.00 0.00 0.00 487967000.00 0.00 2247049000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 66880000.00 309206000.00 1914601000.00 3805316000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36000.00 134936000.00 0.00 -1900000.00 0.00 -1999969000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49599000.00 0.00 0.00 0.00 0.00 -7591000.00 -57190000.00 189890000.00 90000.00 189980000.00 254201000.00 444181000.00 Tax effect on Reameasurement gains/ (losses) 112000.00 Net gain/ (loss) on FVTOCI equity instruments 300000.00 Tax effect on Reameasurement gains/ (losses) 224000.00 Net gain/ (loss) on FVTOCI equity instruments 3150000.00 412000.00 3374000.00 63000.00 417000.00 Exchange differences in translating financial statements of foreign operations 13217000.00 Exchange differences in translating financial statements of foreign operations 16332000.00 13217000.00 16332000.00 0.00 0.00